Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference


MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that it will be participating in H.C. Wainwright’s Bioconnect Conference taking place next week on January 10-13, 2022.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will virtually present on Monday, January 10, 2022. He will provide an update on COVAXIN™, the investigational COVID-19 vaccine the company is co-developing with Bharat Biotech and is currently under review with the U.S. Food and Drug Administration and Health Canada. He will also present information about Ocugen’s breakthrough modifier gene therapy platform and its flagship asset, OCU400, which begins Phase 1/2 clinical trials in Q1 2022.

H.C. Wainwright Bioconnect Conference

  • Date/Time: Presentation available on-demand starting at 7:00 AM Eastern Time on January 10, 2022
  • Registration link: https://journey.ct.events/view/c40afb93-b2a5-46fc-bfbd-ff8d7abd0d43

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.

READ:  COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.